ENSG
The Ensign Group, Inc.175.36
-1.73-0.98%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Healthy M&A pipeline, rising prices
Q&A affirmed a seller-friendly M&A market with rising valuations and diverse sellers, yet Ensign sticks to premiums only for high-quality assets like Utah's Stonehenge, already outperforming. Labor gains trace to director stability slashing agency and overtime. Confident in Medicare VBP via dashboards and CMS foresight. AI pilots leverage partners for admin and clinical edges; construction ramps for bed adds, replacements in mature spots. Behavioral health expands deliberately, as at full Vista Knoll unit. Pipeline brims with opportunity. Bullish tone persists; watch occupancy trajectory, deal discipline.
Key Stats
Market Cap
10.16BP/E (TTM)
31.37Basic EPS (TTM)
5.59Dividend Yield
0%Recent Filings
8-K
Record 2025 results, bold 2026 guide
Ensign Group crushed 2025 with revenue up 18.7% to $5.06B and GAAP EPS soaring 14.1% to $5.84, fueled by 40 new facilities and same-store occupancy hitting record 83.8%. Acquisitions added 17 operations in Q4 alone, boosting skilled days 8.5%. Issues 2026 guidance: $7.41-$7.61 EPS. Strong liquidity fuels more deals.
10-K
FY2025 results
Ensign expanded to 373 facilities with 37,911 skilled nursing beds by December 31, 2025, up from 327 facilities in 2024, driving 18.7% revenue growth to $5.1B on 82.2% occupancy (up 1.7% y/y) and 30.7% skilled mix days (up 0.8%). Same-facility occupancy hit 82.9% while transitioning facilities reached 84.2%, yet Q4 metrics unavailable in the 10-K. Strong cash flow funded $323M in acquisitions and $194M capex; $504M cash bolsters liquidity with no revolver draws. No annual guidance disclosed. Regulatory reimbursement cuts risk quarterly momentum.
10-Q
Q3 FY2025 results
The filing provides only structural details for The Ensign Group's 10-Q covering the quarter ended September 30, 2025—no financial statements, tables, or MD&A figures appear between the markers. Revenue, profitability, margins, EPS, cash flows, debt, and non-GAAP metrics are not disclosed in the 10-Q excerpt. Balance sheet and income statement data for Q3 and 9M FY2025 vs prior periods cannot be analyzed. No M&A, liquidity, or segment drivers are present. Competition remains a key risk from Risk Factors.
8-K
Q3 revenue surges 19.8%
Ensign Group crushed Q3 with revenue up 19.8% to $1.30B and GAAP EPS at $1.42, up 6.0%, fueled by 22 new operations added this quarter alone. Same-facility occupancy hit record 83.0%; transitioning units reached 84.4%. Raised 2025 guidance to $6.48-$6.54 EPS, $5.05B-$5.07B revenue. Acquisitions accelerate growth, yet integration risks loom.
8-K
Director retirement compensation approved
The Ensign Group accelerated vesting of 3,300 restricted stock awards, 21,750 stock options, and 1,000 Standard Bearer restricted shares for retiring director Christopher Christensen, effective August 21, 2025, alongside a $2.07 million cash bonus for 2025 services and up to $150,000 health insurance subsidy over five years. The company will repurchase his 19,726 Standard Bearer common shares and one preferred share for $287,393 at fair market value. Christensen steps down September 1 but offers advisory services up to one year at $100,000 annually. This smooths the board transition without operational disruptions.
IPO
Website
Employees
Sector
Industry
BKD
Brookdale Senior Living Inc.
10.49+0.19
BMGL
Basel Medical Group Ltd
0.76-0.10
EHAB
Enhabit, Inc.
9.61-0.08
EHC
Encompass Health Corporation
108.01+0.42
HCA
HCA Healthcare, Inc.
469.79-7.19
HCSG
Healthcare Services Group, Inc.
19.09-0.27
NHC
National HealthCare Corporation
138.93-0.94
PACS
PACS Group, Inc.
34.20-0.55
PNTG
The Pennant Group, Inc.
29.73+0.00
SNDA
Sonida Senior Living, Inc.
31.53-0.06